One year ago today, Donald Trump stood in the White House Rose Garden and declared Liberation Day. Sweeping tariffs on imports from dozens of countries — countered, revised, and partially struck down by the Supreme Court, then replaced with a 15% global baseline — have reshaped global supply chains and forced American companies to rethink how they source everything from steel to packaging.
Most industries adapted. Cannabis couldn’t.
That’s not a failure of ingenuity. It’s a structural trap that gets almost no attention in the broader tariff coverage: cannabis operators are uniquely, almost categorically, unable to execute the defensive moves that kept other industries afloat.
Where the Exposure Lives
The cannabis industry’s single biggest tariff vulnerability is vape hardware. The overwhelming majority of vape cartridges, batteries, and hardware sold in U.S. dispensaries are manufactured in China. Estimates from operators and trade groups put Chinese-sourced vape hardware at somewhere between 70% and 85% of total U.S. market supply. There is no meaningful domestic alternative at scale.
Beyond hardware, the exposure is layered. Packaging — child-resistant containers, mylar bags, glass jars — largely sources from China and Vietnam. Grow lighting: much of the LED technology used in licensed cultivation comes from Chinese manufacturers. Lab equipment: extraction hardware, testing instruments, chromatography components. The inputs list is long, and it’s overwhelmingly Asian-sourced.
The tariff math is brutal on its own. A 15% baseline tariff on a vape cartridge that was already operating on compressed margins adds costs that can’t easily be recovered in price. But the tariff cost is actually the secondary problem. The primary problem is what’s missing.
The Tools Everyone Else Has
When Procter & Gamble faced a $1 billion annual tariff hit, it raised prices on 25% of its products. When Constellation Brands took a $20 million hit on its beer ingredients, it passed costs through and told investors in a structured earnings call with guidance revisions.
Cannabis operators have neither option in meaningful form.
Pricing power is largely exhausted. The legal cannabis market has been in a multi-year deflationary cycle. Average flower prices in mature markets like Colorado, California, and Oregon have fallen 30-50% from their post-legalization peaks. Passing tariff costs to consumers in a market where illicit competition is a constant and consumer price sensitivity is acute is a losing proposition for most operators. The ones who try it lose volume; the ones who absorb it lose margin.
Capital markets access is essentially closed. When mainstream companies need to restructure supply chains — moving suppliers from China to Vietnam, Mexico, or domestic alternatives — they borrow money, take on strategic partners, or issue equity. Cannabis MSOs operating on the OTC markets, locked out of major exchanges, still paying 280E tax rates on gross profit rather than net income, and with seven of the sector’s largest operators already under creditor control, do not have this option. Curaleaf recently extended some of its debt load; it didn’t reduce it. The capital available for supply chain restructuring simply does not exist.
Banking infrastructure is broken. The ability to wire funds internationally, manage supplier relationships through normal treasury operations, hedge currency exposure, or use basic trade finance instruments — letters of credit, supply chain financing — requires banking relationships that cannabis operators are still largely denied under federal prohibition. Some larger MSOs have navigated this with creative workarounds, but those workarounds don’t scale, and they don’t make tariff mitigation any easier.
The Structural Bind
This is what makes the tariff story different for cannabis than for almost any other sector. Other industries are disadvantaged by tariffs. Cannabis operators are disadvantaged and structurally prevented from responding.
The NCV index tracker put it plainly in this week’s newsletter: the Global Cannabis Stock Index has now declined 88.2% from its 2020 peak, and 20.2% year-to-date in 2026 alone. That’s the cumulative weight of 280E taxation, price compression, debt overhang, and regulatory friction. Tariff exposure doesn’t cause that decline on its own — but it adds pressure on margins that have almost no room left.
The operators best positioned to manage tariff exposure share a few characteristics: vertical integration that limits how many external inputs they purchase; enough scale to have negotiated longer supply contracts before tariff increases hit; and some degree of geographic concentration that lets them rationalize input sourcing. Glass House Brands, for example — which runs one of the largest greenhouse cultivation operations in the country out of California — has structural input-cost advantages that most MSOs simply don’t. It was one of only three GCSI members to post positive returns in March.
The rest of the sector is caught between a tariff regime it can’t hedge, a capital market it can’t access, and a regulatory structure that makes the normal corporate survival toolkit unavailable.
What to Watch
Congress could meaningfully address part of this by passing banking reform — SAFE Banking, the CLIMB Act, or any legislation that gives operators access to normal financial services. None of those are moving fast enough to matter this year.
Rescheduling, if it proceeds, would eliminate 280E taxation — the single biggest lever on operator cash flow — and potentially open a path to more normal capital markets access. The executive order exists. The timeline does not.
In the meantime, operators are doing what operators do when cornered: cutting costs, consolidating, and hoping the macro stabilizes before the balance sheet doesn’t. The tariff regime is one more headwind in a sector that’s been flying into the wind for five years.
One year after Liberation Day, most American industries are cautiously optimistic they’ve found their footing. The cannabis industry is still waiting for the tools to look for theirs.
Related Stories
Responses